NSG BioLabs banks $14.5m, eyes expanding facilities via partnerships

Daphne Teo, CEO and founder of NSG BioLabs / Photo credit: NSG BioLabs

Biotech incubator NSG BioLabs has partnered with government agency Enterprise Singapore and life sciences giant Merck to give biotech startups access to resources for R&D initiatives, covering areas such as funding, technical skills, and networking opportunities.

The Singapore-based firm has also raised a US$15.4 million in a funding round led by Celadon Partners and ClavystBio, a Temasek biotech venture platform. With the fresh funds, NSG Biolabs plans to expand its products, services, and facilities across Singapore and Southeast Asia.

Through its co-working laboratories and office spaces, NSG BioLabs has lent a hand to businesses specializing in precision medicine, nucleic acids, AI-enabled drug discovery, and synthetic biology since opening its first site in 2019,  The company has hosted over 40 businesses to date.

Since its launch, NSG BioLabs has been part of Enterprise Singapore’s Startup SG Accelerator program. This renewed collaboration aims to invest in “high-potential” biotech startups and speed up their development and market release.

Meanwhile, partnering with Merck enables NSG BioLabs residents exclusive access to the former’s range of reagents and life sciences equipment. Residents can also tap into Merck’s biopharma processing expertise in scaling up production.

Primarily serving as a support base for biotech startups, NSG BioLabs offers shared and private labs and offices with Biosafety Level 2 (BSL-2) certification. The company now maintains three sites totaling 35,000 square feet at Singapore’s Biopolis.

See also: Singapore could lose more biotech firms